Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocriplasmin Infusion for CRVO
NCT02747030Phase 1Completed
- Sponsor
- UZ Leuven
- Start
- Dec 2016
- Primary completion
- Aug 2017
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ocriplasmin in central retinal vein occlusion (CRVO), sponsored by UZ Leuven. Primary endpoints: Feasibility and Safety at 2 weeks. Started Dec 2016; status: completed.
02
Drugs
ocriplasmin
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT02747030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02747030.